{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T18:05:41Z","timestamp":1765908341473,"version":"3.48.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Third People\u2019s Hospital of Xinjiang Uygur Autonomous Region","award":["2024006"],"award-info":[{"award-number":["2024006"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82403761"],"award-info":[{"award-number":["82403761"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04449-8","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:15:53Z","timestamp":1761214553000},"page":"1380-1389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive and prognostic role of Neutrophil-to-Lymphocyte ratio in patients with advanced thyroid cancer treated with targeted therapy"],"prefix":"10.1007","volume":"90","author":[{"given":"Tuerhong","family":"Diliyaer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueyan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xixi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuerxun","family":"Yilidana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"4449_CR1","doi-asserted-by":"publisher","unstructured":"R.V. Lloyd et al., (2023). WHO Classification of Tumours of Endocrine Organs (5th Edition): Updates on Thyroid Carcinoma. Endocrine Pathology, 34(1), 1\u201315. https:\/\/doi.org\/10.1007\/s12022-023-09759-z","DOI":"10.1007\/s12022-023-09759-z"},{"issue":"3","key":"4449_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"H. Sung et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 71(3), 209\u2013249 (2021). https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"Cancer J. Clin."},{"key":"4449_CR3","doi-asserted-by":"crossref","unstructured":"D.W. Chen, B.H.H. Lang, D.S.A. McLeod, K. Newbold, M.R. Haymart, Thyroid cancer. Lancet. 2023;401(10387):1531\u20131544. doi: 10.1016\/S0140-6736(23)00020-X. Epub 2023 Apr 3. PMID: 37023783","DOI":"10.1016\/S0140-6736(23)00020-X"},{"key":"4449_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fendo.2020.00082","volume":"11","author":"D Laha","year":"2020","unstructured":"D. Laha, N. Nilubol, M. Boufraqech, New therapies for advanced thyroid cancer. Front. Endocrinol. (Lausanne). 11, 82 (2020). https:\/\/doi.org\/10.3389\/fendo.2020.00082. PMID: 32528402; PMCID: PMC7257776","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"13","key":"4449_CR5","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1002\/cam4.3970","volume":"10","author":"M Zhai","year":"2021","unstructured":"M. Zhai, D. Zhang, J. Long, Y. Gong, F. Ye, S. Liu, Y. Li, The global burden of thyroid cancer and its attributable risk factor in 195 countries and territories: A systematic analysis for the global burden of disease study. Cancer Med. 10(13), 4542\u20134554 (2021). Epub 2021 May 18. PMID: 34002931; PMCID: PMC8267141","journal-title":"Cancer Med."},{"issue":"6","key":"4449_CR6","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1210\/er.2019-00007","volume":"40","author":"ME Cabanillas","year":"2019","unstructured":"M.E. Cabanillas, M. Ryder, C. Jimenez, Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr. Rev. 40(6), 1573\u20131604 (2019). https:\/\/doi.org\/10.1210\/er.2019-00007. PMID: 31322645; PMCID: PMC7341904","journal-title":"Endocr. Rev."},{"issue":"11","key":"4449_CR7","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1089\/thy.2016.0247","volume":"26","author":"B Xu","year":"2016","unstructured":"B. Xu, T. Ibrahimpasic, L. Wang, M.M. Sabra, J.C. Migliacci, R.M. Tuttle, I. Ganly, R. Ghossein, Clinicopathologic features of fatal Non-Anaplastic follicular Cell-Derived thyroid carcinomas. Thyroid. 26(11), 1588\u20131597 (2016). https:\/\/doi.org\/10.1089\/thy.2016.0247. Epub 2016 Sep 7. PMID: 27480016; PMCID: PMC5105347","journal-title":"Thyroid"},{"issue":"8","key":"4449_CR8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1089\/thy.2012.0403","volume":"23","author":"T Ibrahimpasic","year":"2013","unstructured":"T. Ibrahimpasic, R. Ghossein, D.L. Carlson, N. Chernichenko, I. Nixon, F.L. Palmer, N.Y. Lee, A.R. Shaha, S.G. Patel, R.M. Tuttle, A.J. Balm, J.P. Shah, I. Ganly, Poorly differentiated thyroid carcinoma presenting with gross extrathyroidal extension: 1986\u20132009 memorial Sloan-Kettering cancer center experience. Thyroid. 23(8), 997\u20131002 (2013). https:\/\/doi.org\/10.1089\/thy.2012.0403. Epub 2013 Jul 17. PMID: 23311700","journal-title":"Thyroid"},{"issue":"4","key":"4449_CR9","doi-asserted-by":"publisher","first-page":"188928","DOI":"10.1016\/j.bbcan.2023.188928","volume":"1878","author":"L Zhang","year":"2023","unstructured":"L. Zhang, Q. Feng, J. Wang, Z. Tan, Q. Li, M. Ge, Molecular basis and targeted therapy in thyroid cancer: progress and opportunities. Biochim. Biophys. Acta Rev. Cancer. 1878(4), 188928 (2023). https:\/\/doi.org\/10.1016\/j.bbcan.2023.188928. Epub 2023 May 29. PMID: 37257629","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"4","key":"4449_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1089\/thy.2023.0547","volume":"34","author":"M Tahara","year":"2024","unstructured":"M. Tahara, N. Kiyota, H. Imai, S. Takahashi, A. Nishiyama, S. Tamura, Y. Shimizu, S. Kadowaki, K.I. Ito, M. Toyoshima, Y. Hirashima, S. Ueno, I. Sugitani, A phase 2 study of Encorafenib in combination with binimetinib in patients with metastatic BRAF-Mutated thyroid cancer in Japan. Thyroid. 34(4), 467\u2013476 (2024). https:\/\/doi.org\/10.1089\/thy.2023.0547. Epub 2024 Mar 14. PMID: 38343359","journal-title":"Thyroid"},{"issue":"21","key":"4449_CR11","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1200\/JCO.20.03093","volume":"39","author":"LJ Wirth","year":"2021","unstructured":"L.J. Wirth, M.S. Brose, E.J. Sherman, L. Licitra, M. Schlumberger, S.I. Sherman, K.C. Bible, B. Robinson, P. Rodien, Y. Godbert, De La C. Fouchardiere, K. Newbold, C. Nutting, S. Misir, R. Xie, A. Almonte, W. Ye, M.E. Cabanillas, Open-Label, Single-Arm, Multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer. J. Clin. Oncol. 39(21), 2359\u20132366 (2021). Epub 2021 May 7. PMID: 33961488; PMCID: PMC8280094","journal-title":"J. Clin. Oncol."},{"key":"4449_CR12","doi-asserted-by":"publisher","unstructured":"L. Boucai, M. Zafereo, M.E. Cabanillas, Thyroid Cancer, A Review. JAMA. 2024;331(5):425\u2013435. https:\/\/doi.org\/10.1001\/jama.2023.26348. PMID: 38319329","DOI":"10.1001\/jama.2023.26348"},{"issue":"2","key":"4449_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3803\/EnM.2023.1854","volume":"39","author":"CA Kim","year":"2024","unstructured":"C.A. Kim, M. Kim, M. Jin, H.K. Kim, M.J. Jeon, D.J. Lim, B.H. Kim, H.C. Kang, W.B. Kim, D.Y. Shin, W.G. Kim, Prognostic roles of inflammatory biomarkers in Radioiodine-Refractory thyroid cancer treated with lenvatinib. Endocrinol. Metab. (Seoul). 39(2), 334\u2013343 (2024). Epub 2024 Apr 4. PMID: 38572536; PMCID: PMC11066453","journal-title":"Endocrinol. Metab. (Seoul)"},{"issue":"5","key":"4449_CR14","doi-asserted-by":"publisher","first-page":"e2311181","DOI":"10.1001\/jamanetworkopen.2023.11181","volume":"6","author":"C Aggarwal","year":"2023","unstructured":"C. Aggarwal, R. Ben-Shachar, Y. Gao, S.W. Hyun, Z. Rivers, C. Epstein, K. Kaneva, C. Sangli, H. Nimeiri, J. Patel, Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy. JAMA Netw. Open. 6(5), e2311181 (2023). https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.11181. PMID: 37129893; PMCID: PMC10155064","journal-title":"JAMA Netw. Open."},{"key":"4449_CR15","doi-asserted-by":"publisher","unstructured":"D.T. Hoang, G. Dinstag, E.D. Shulman, L.C. Hermida, D.S. Ben-Zvi, E. Elis, K. Caley, S.J. Sammut, S. Sinha, N. Sinha, C.H. Dampier, C. Stossel, T. Patil, A. Rajan, W. Lassoued, J. Strauss, S. Bailey, C. Allen, J. Redman, T. Beker, P. Jiang, T. Golan, S. Wilkinson, A.G. Sowalsky, S.R. Pine, C. Caldas, J.L. Gulley, K. Aldape, R. Aharonov, E.A. Stone, E. Ruppin, A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics. Nat Cancer. 2024;5(9):1305\u20131317. https:\/\/doi.org\/10.1038\/s43018-024-00793-2. Epub 2024 Jul 3. PMID: 38961276","DOI":"10.1038\/s43018-024-00793-2"},{"key":"4449_CR16","doi-asserted-by":"publisher","unstructured":"A. Nayarisseri, R. Khandelwal, P. Tanwar, M. Madhavi, D. Sharma, G. Thakur, A. Speck-Planche, S.K. Singh, Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery. Curr Drug Targets. 2021;22(6):631\u2013655. https:\/\/doi.org\/10.2174\/1389450122999210104205732. PMID: 33397265","DOI":"10.2174\/1389450122999210104205732"},{"issue":"7894","key":"4449_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41586-021-04278-5","volume":"601","author":"SJ Sammut","year":"2022","unstructured":"S.J. Sammut, M. Crispin-Ortuzar, S.F. Chin, E. Provenzano, H.A. Bardwell, W. Ma, W. Cope, A. Dariush, S.J. Dawson, J.E. Abraham, J. Dunn, L. Hiller, J. Thomas, D.A. Cameron, J.M.S. Bartlett, L. Hayward, P.D. Pharoah, F. Markowetz, O.M. Rueda, H.M. Earl, C. Caldas, Multi-omic machine learning predictor of breast cancer therapy response. Nature. 601(7894), 623\u2013629 (2022). https:\/\/doi.org\/10.1038\/s41586-021-04278-5. Epub 2021 Dec 7. PMID: 34875674; PMCID: PMC8791834","journal-title":"Nature"},{"key":"4449_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fendo.2020.00102","volume":"11","author":"A Prete","year":"2020","unstructured":"A. Prete, P. Borges de Souza, S. Censi, M. Muzza, N. Nucci, M. Sponziello, Update on fundamental mechanisms of thyroid cancer. Front. Endocrinol. (Lausanne). 11, 102 (2020). https:\/\/doi.org\/10.3389\/fendo.2020.00102. PMID: 32231639; PMCID: PMC7082927","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"12","key":"4449_CR19","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.3390\/biom13121803","volume":"13","author":"M Mosca","year":"2023","unstructured":"M. Mosca, M.C. Nigro, R. Pagani, De A. Giglio, Di A. Federico, Neutrophil-to-Lymphocyte ratio (NLR) in NSCLC, Gastrointestinal, and other solid tumors: immunotherapy and beyond. Biomolecules. 13(12), 1803 (2023). https:\/\/doi.org\/10.3390\/biom13121803. PMID: 38136673; PMCID: PMC10741961","journal-title":"Biomolecules"},{"key":"4449_CR20","doi-asserted-by":"publisher","unstructured":"A.J. Templeton, M.G. McNamara, B. \u0160eruga, F.E. Vera-Badillo, P. Aneja, A. Oca\u00f1a, R. Leibowitz-Amit, G. Sonpavde, J.J. Knox, B. Tran, I.F. Tannock, E. Amir, Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. https:\/\/doi.org\/10.1093\/jnci\/dju124. PMID: 24875653","DOI":"10.1093\/jnci\/dju124"},{"key":"4449_CR21","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"A.J. Templeton, M.G. McNamara, B. Seruga et al., Prognostic role of neutrophilto-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl. Cancer Inst. 106, dju124 (2014)","journal-title":"J. Natl. Cancer Inst."},{"key":"4449_CR22","doi-asserted-by":"publisher","first-page":"e938499","DOI":"10.12659\/MSM.938499","volume":"28","author":"GNA Winarno","year":"2022","unstructured":"G.N.A. Winarno, A.I. Mulyantari, A. Kurniadi, D. Suardi, Z. Zulvayanti, N. Trianasari, Predicting chemotherapy resistance in gestational trophoblastic neoplasia: ratio of Neutrophils, Lymphocytes, Monocytes, and platelets. Med. Sci. Monit. 28, e938499 (2022). https:\/\/doi.org\/10.12659\/MSM.938499. PMID: 36477073; PMCID: PMC9745950","journal-title":"Med. Sci. Monit."},{"issue":"1","key":"4449_CR23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","volume":"12","author":"C Valero","year":"2021","unstructured":"C. Valero, M. Lee, D. Hoen, K. Weiss, D.W. Kelly, P.S. Adusumilli, P.K. Paik, G. Plitas, M. Ladanyi, M.A. Postow, C.E. Ariyan, A.N. Shoushtari, V.P. Balachandran, A.A. Hakimi, A.M. Crago, K.C. Long Roche, J.J. Smith, I. Ganly, R.J. Wong, S.G. Patel, J.P. Shah, N.Y. Lee, N. Riaz, J. Wang, A. Zehir, M.F. Berger, T.A. Chan, V.E. Seshan, L.G.T. Morris, Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat. Commun. 12(1), 729 (2021). https:\/\/doi.org\/10.1038\/s41467-021-20935-9. PMID: 33526794; PMCID: PMC7851155","journal-title":"Nat. Commun."},{"issue":"1","key":"4449_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13048-021-00902-0","volume":"14","author":"M Liontos","year":"2021","unstructured":"M. Liontos, A. Andrikopoulou, K. Koutsoukos, C. Markellos, E. Skafida, O. Fiste, M. Kaparelou, N. Thomakos, D. Haidopoulos, A. Rodolakis, M.A. Dimopoulos, F. Zagouri, Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy. J. Ovarian Res. 14(1), 148 (2021). https:\/\/doi.org\/10.1186\/s13048-021-00902-0. PMID: 34724958; PMCID: PMC8561989","journal-title":"J. Ovarian Res."},{"key":"4449_CR25","doi-asserted-by":"publisher","first-page":"107327482413090","DOI":"10.1177\/10732748241309048","volume":"31","author":"Gao Q.","year":"2024","unstructured":"Q. Gao, M. Quan, L. Zhang, Y. Ran, J. Zhong, B. Wang, Neutrophil-To-Lymphocyte ratio as a prognostic indicator in thyroid cancer. Cancer Control 2024;31:10732748241309048 https:\/\/doi.org\/10.1177\/10732748241309048","journal-title":"Cancer Control"},{"key":"4449_CR26","doi-asserted-by":"publisher","unstructured":"N. Treistman, L.B.C.P. Cavalcante, F. Gonzalez, P.I.W. Fernandes, de F.A. Andrade, P.A. Garcis Alves-Junior, R. Corbo, D.A. Bulzico, F. Vaisman, Neutrophil-to-lymphocyte ratio as an independent factor for worse prognosis in radioiodine refractory thyroid cancer patients. Endocrine. 2023;81(1):141\u2013148. https:\/\/doi.org\/10.1007\/s12020-023-03340-8. Epub 2023 Mar 11. PMID: 36905576","DOI":"10.1007\/s12020-023-03340-8"},{"issue":"1","key":"4449_CR27","first-page":"55","volume":"68","author":"ND Perrier","year":"2018","unstructured":"N.D. Perrier, J.D. Brierley, R.M. Tuttle, Differentiated and anaplastic thyroid carcinoma: major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J. Clin. 68(1), 55\u201363 (2018)","journal-title":"CA Cancer J. Clin."},{"key":"4449_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"L.H. Schwartz, L. Seymour, S. Liti\u00e8re, R. Ford, S. Gwyther, S. Mandrekar, L. Shankar, J. Bogaerts, A. Chen, J. Dancey, W. Hayes, F.S. Hodi, O.S. Hoekstra, E.P. Huang, N. Lin, Y. Liu, P. Therasse, J.D. Wolchok, de E. Vries, RECIST 1.1 - Standardisation and disease-specific adaptations: perspectives from the RECIST working group. Eur. J. Cancer. 62, 138\u2013145 (2016). Epub 2016 May 26. PMID: 27237360; PMCID: PMC5737786","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"4449_CR29","doi-asserted-by":"publisher","first-page":"7172","DOI":"10.1245\/s10434-023-14031-z","volume":"30","author":"JY Chen","year":"2023","unstructured":"J.Y. Chen, N.S. Huang, W.J. Wei, J.Q. Hu, Y.M. Cao, Q. Shen, Z.W. Lu, Y.L. Wang, Y. Wang, Q.H. Ji, The efficacy and safety of Surufatinib combined with anti PD-1 antibody Toripalimab in neoadjuvant treatment of locally advanced differentiated thyroid cancer: A phase II study. Ann. Surg. Oncol. 30(12), 7172\u20137180 (2023). https:\/\/doi.org\/10.1245\/s10434-023-14031-z. Epub 2023 Aug 5. PMID: 37543550","journal-title":"Ann. Surg. Oncol."},{"key":"4449_CR30","doi-asserted-by":"publisher","first-page":"1372553","DOI":"10.3389\/fendo.2024.1372553","volume":"15","author":"M Guo","year":"2024","unstructured":"M. Guo, Y. Sun, Y. Wei, J. Xu, C. Zhang, Advances in targeted therapy and biomarker research in thyroid cancer. Front. Endocrinol. (Lausanne). 15, 1372553 (2024). https:\/\/doi.org\/10.3389\/fendo.2024.1372553. PMID: 38501105; PMCID: PMC10944873","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"6","key":"4449_CR31","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-22-1031","volume":"29","author":"KB Kennel","year":"2023","unstructured":"K.B. Kennel, M. Bozlar, De A.F. Valk, F.R. Greten, Cancer-Associated fibroblasts in inflammation and antitumor immunity. Clin. Cancer Res. 29(6), 1009\u20131016 (2023). https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1031. PMID: 36399325; PMCID: PMC10011884","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"4449_CR32","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"S.I. Grivennikov, F.R. Greten, M. Karin, Immunity, inflammation, and cancer. Cell. 140(6), 883\u2013899 (2010). https:\/\/doi.org\/10.1016\/j.cell.2010.01.025. PMID: 20303878; PMCID: PMC2866629","journal-title":"Cell"},{"key":"4449_CR33","doi-asserted-by":"publisher","unstructured":"D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u2009\u2013\u200974. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013. PMID: 21376230","DOI":"10.1016\/j.cell.2011.02.013"},{"issue":"8","key":"4449_CR34","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s10654-021-00752-6","volume":"36","author":"TH N\u00f8st","year":"2021","unstructured":"T.H. N\u00f8st, K. Alcala, I. Urbarova, K.S. Byrne, F. Guida, T.M. Sandanger, M. Johansson, Systemic inflammation markers and cancer incidence in the UK biobank. Eur. J. Epidemiol. 36(8), 841\u2013848 (2021). https:\/\/doi.org\/10.1007\/s10654-021-00752-6. Epub 2021 May 25. PMID: 34036468; PMCID: PMC8416852","journal-title":"Eur. J. Epidemiol."},{"issue":"9","key":"4449_CR35","doi-asserted-by":"publisher","first-page":"e048324","DOI":"10.1136\/bmjopen-2020-048324","volume":"11","author":"Y Jiang","year":"2021","unstructured":"Y. Jiang, D. Xu, H. Song, B. Qiu, D. Tian, Z. Li, Y. Ji, J. Wang, Inflammation and nutrition-based biomarkers in the prognosis of oesophageal cancer: a systematic review and meta-analysis. BMJ Open. 11(9), e048324 (2021). https:\/\/doi.org\/10.1136\/bmjopen-2020-048324. PMID: 34593492; PMCID: PMC8487212","journal-title":"BMJ Open."},{"key":"4449_CR36","doi-asserted-by":"publisher","unstructured":"E. Eraslan, Y.G. Adas, F. Yildiz, A.I. Gulesen, C. Karacin, U.Y. Arslan, Systemic Immune-inflammation Index (SII) Predicts Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. J Coll Physicians Surg Pak. 2021;31(4):399\u2013404. https:\/\/doi.org\/10.29271\/jcpsp.2021.04.399. PMID: 33866724","DOI":"10.29271\/jcpsp.2021.04.399"},{"issue":"1","key":"4449_CR37","doi-asserted-by":"publisher","first-page":"2476870","DOI":"10.1080\/20565623.2025.2476870","volume":"11","author":"Y Xie","year":"2025","unstructured":"Y. Xie, Q. Yu, Y. Zhu, W. Wu, R. Xiao, N. Wang, L. Zhu, P. Li, T. Chen, The value of peripheral blood inflammation markers in risk assessment and prediction of lung cancer. Future Sci. OA 11(1), 2476870 (2025). Epub 2025 Mar 13. PMID: 40079245; PMCID: PMC11916372","journal-title":"Future Sci. OA"},{"key":"4449_CR38","doi-asserted-by":"publisher","first-page":"812319","DOI":"10.3389\/fonc.2021.812319","volume":"11","author":"S Wang","year":"2022","unstructured":"S. Wang, Y. Ji, Y. Chen, P. Du, Y. Cao, X. Yang, J. Ma, Z. Yu, Y. Yang, The values of systemic Immune-Inflammation index and Neutrophil-Lymphocyte ratio in the localized prostate cancer and benign prostate hyperplasia: A retrospective clinical study. Front. Oncol. 11, 812319 (2022). https:\/\/doi.org\/10.3389\/fonc.2021.812319. PMID: 35047413; PMCID: PMC8763322","journal-title":"Front. Oncol."},{"issue":"3","key":"4449_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","volume":"4","author":"L Mezquita","year":"2018","unstructured":"L. Mezquita, E. Auclin, R. Ferrara, M. Charrier, J. Remon, D. Planchard, S. Ponce, L.P. Ares, L. Leroy, C. Audigier-Valette, E. Felip, J. Zer\u00f3n-Medina, P. Garrido, S. Brosseau, G. Zalcman, J. Mazieres, C. Caramela, J. Lahmar, J. Adam, N. Chaput, J.C. Soria, B. Besse, Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced Non-Small cell lung cancer. JAMA Oncol. 4(3), 351\u2013357 (2018). https:\/\/doi.org\/10.1001\/jamaoncol.2017.4771. PMID: 29327044; PMCID: PMC5885829","journal-title":"JAMA Oncol."},{"key":"4449_CR40","doi-asserted-by":"crossref","unstructured":"R. Zahorec, Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy. 2021;122(7):474\u2013488. doi: 10.4149\/BLL_2021_078. PMID: 34161115","DOI":"10.4149\/BLL_2021_078"},{"issue":"8","key":"4449_CR41","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1007\/s00405-022-07274-1","volume":"279","author":"A Yanni","year":"2022","unstructured":"A. Yanni, T. Buset, C. Bouland, I. Loeb, J.R. Lechien, A. Rodriguez, F. Journe, S. Saussez, D. Dequanter, Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck cancer with lung metastasis: a retrospective study. Eur. Arch. Otorhinolaryngol. 279(8), 4103\u20134111 (2022). https:\/\/doi.org\/10.1007\/s00405-022-07274-1. Epub 2022 Jan 31. PMID: 35099595","journal-title":"Eur. Arch. Otorhinolaryngol."},{"issue":"2","key":"4449_CR42","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12020-023-03348-0","volume":"81","author":"M Jin","year":"2023","unstructured":"M. Jin, M. Kim, M.J. Jeon, E.Y. Kim, D.Y. Shin, B.H. Kim, W.B. Kim, Y.K. Shong, D.J. Lim, W.G. Kim, Inflammatory biomarkers predict outcomes of patients with radioactive iodine refractory thyroid cancer treated with Sorafenib. Endocrine. 81(2), 298\u2013305 (2023). https:\/\/doi.org\/10.1007\/s12020-023-03348-0. Epub 2023 Mar 16. PMID: 36928602","journal-title":"Endocrine"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04449-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04449-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04449-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T18:03:37Z","timestamp":1765908217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04449-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4449"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04449-8","relation":{},"ISSN":["1559-0100"],"issn-type":[{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}